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Objectives: To determine the effectiveness of noninvasive positive pressure ventilation 
(NIPPV), and the factors predicting failure of NIPPV in acute respiratory failure (ARF) due to 
chronic obstructive pulmonary disease (COPD) versus other causes of ARF.
Patients and methods: This was a prospective observational study and all patients with 
ARF requiring NIPPV over a one-and-a-half year period were enrolled in the study. We 
recorded the etiology of ARF and prospectively collected the data for heart rate, respiratory rate, 
arterial blood gases (pH, partial pressure of oxygen in the arterial blood [PaO2], partial pres-
sure of carbon dioxide in arterial blood [PaCO2]) at baseline, one and four hours. The patients 
were further classiﬁ  ed into two groups based on the etiology of ARF as COPD–ARF and ARF 
due to other causes. The primary outcome was the need for endotracheal intubation during the 
intensive care unit (ICU) stay.
Results: During the study period, 248 patients were admitted in the ICU and of these 63 
(25.4%; 24, COPD–ARF, 39, ARF due to other causes; 40 male and 23 female patients; mean 
[standard deviation] age of 45.7 [16.6] years) patients were initiated on NIPPV. Patients with 
ARF secondary to COPD were older, had higher APACHE II scores, lower respiratory rates, 
lower pH and higher PaCO2 levels compared to other causes of ARF. After one hour there was 
a signiﬁ  cant decrease in respiratory rate and heart rate and decline in PaCO2 levels with increase 
in pH and PaO2 levels in patients successfully managed with NIPPV. However, there was no 
difference in improvement of clinical and blood gas parameters between the two groups except 
the rate of decline of pH at one and four hours and PaCO2 at one hour which was signiﬁ  cantly 
faster in the COPD group. NIPPV failures were signiﬁ  cantly higher in ARF due to other causes 
(15/39) than in ARF–COPD (3/24) (p = 0.03). The mean ICU and hospital stay and the hospital 
mortality were similar in the two groups. In the multivariate logistic regression model (after 
adjusting for gender, APACHE II scores and improvement in respiratory rate, pH, PaO2 and 
PaCO2 at one hour) only the etiology of ARF, ie, ARF–COPD, was associated with a decreased 
risk of NIPPV failure (odds ratio 0.23; 95% conﬁ  dence interval, 0.58–0.9).
Conclusions: NIPPV is more effective in preventing endotracheal intubation in ARF due to 
COPD than other causes, and the etiology of ARF is an important predictor of NIPPV failure.
Keywords: noninvasive ventilation, noninvasive positive pressure ventilation, acute respira-
tory failure, chronic obstructive pulmonary disease, CPAP, bilevel positive airway pressure, 
pneumonia, ALI, ARDS
Introduction
The ﬁ  rst-line treatment of patients with acute respiratory failure (ARF) is mechani-
cal ventilation. Patients with ARF can be ventilated either with positive or negative 
pressure, invasively or noninvasively. Noninvasive ventilation (NIV) is the provision International Journal of COPD 2008:3(4) 738
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of ventilatory support to the lungs without the use of an 
endotracheal airway. NIV has revolutionized the manage-
ment of ARF, and has been applied in diverse forms of 
ARF (Brochard et al 2002). It not only reduces the need for 
endotracheal intubation and its associated complications like 
airway trauma, pneumonia and others but also reduces the 
complications associated with stay in the intensive care unit 
(ICU), the length of hospital stay, and mortality in selected 
group of patients (Brochard 2003; Liesching et al 2003). 
However, the evidence for the use of NIV remains strongest 
in patients with hypercapnic ARF due to exacerbations of 
chronic obstructive pulmonary disease (COPD) and cardio-
genic pulmonary edema (Ram et al 2004; Agarwal et al 2005). 
Positive pressure therapy can be delivered noninvasively by 
noninvasive positive pressure ventilation (NIPPV) (or bi-level 
positive airway pressure) and continuous positive airway pres-
sure (CPAP). In NIPPV, two different pressures are used viz. 
inspiratory positive airway pressure (IPAP) and expiratory 
positive airway pressure (EPAP), whereas CPAP maintains 
a constant positive airway pressure throughout the respiratory 
cycle. Theoretically, NIPPV may confer an advantage over 
CPAP by reducing the work of breathing during inspiration 
by providing additional inspiratory pressure. While there is 
strong evidence to support the use of NIPPV in COPD, the role 
of NIV in hypoxemic ARF unrelated to CPE is controversial. 
Two recent meta-analyses did not ﬁ  nd any strong evidence 
to support the role of NIV in acute hypoxemic respiratory 
failure and acute respiratory distress syndrome respectively 
(Keenan et al 2004; Agarwal et al 2006).
The application of NIPPV in the management of patients 
with ARF is not associated with a 100% success rate. In many 
patients application of NIV is clearly insufﬁ  cient as it does 
not obtain adequate ventilation and eventually endotracheal 
intubation and invasive mechanical ventilation is required for 
the management of respiratory failure. Also, some patients 
will initially beneﬁ  t from NIPPV (for hours to few days) but 
will then deteriorate and require intubation. The failure rates 
of NIPPV can range from 5% to 50% in different studies 
depending on the etiology and severity of ARF (Plant et al 
2001; Nava and Ceriana 2004; Confalonieri et al 2005; Phua 
et al 2005). Failure to identify the patients who are likely to 
fail NIPPV can cause inappropriate delay in intubation; this 
can lead to clinical deterioration and increased morbidity 
and mortality (Nava and Ceriana 2004). Thus, it becomes 
important to ascertain the factors associated with NIV failure 
so that we can identify the high-risk subset of patients who 
are likely to fail a trial of NIV. This subject has been widely 
researched with abundant data published from the developed 
world (Soo Hoo et al 1994; Cheung et al 2000; Lightowler 
and Elliott 2000; Antonelli et al 2001; Azoulay et al 2001; 
Carlucci et al 2001; Plant et al 2001; Afessa et al 2002; Hess 
2004; Nava and Ceriana 2004; Jaber et al 2005; Phua et al 
2005; Budweiser et al 2007; Lellouche 2007). However, there 
is still a paucity of literature from India on NIV despite the 
fact that this modality of treatment can assume signiﬁ  cant 
relevance in resource constrained setting. In fact, there are 
only two published original articles investigating the role of 
NIV from India (Singh et al 2006; George et al 2007). The 
aim of this study is to describe the effectiveness of NIPPV in 
ARF due to COPD vs other conditions, and also to describe 
the factors predicting failure of NIPPV from a respiratory 
intensive care unit (ICU) in North India.
Patients and methods
This was a prospective observational study conducted in the 
respiratory intensive care unit (RICU) of this institute. All 
patients requiring NIPPV for ARF between July 2001 and 
December 2002 were enrolled in the study. The study was 
cleared by the Institute Ethics Committee and written consent 
was obtained from all patients or the next of kin.
Patients were included in the study if they met the deﬁ  ni-
tion of acute respiratory failure deﬁ  ned by the presence of 
both of the following criteria: (a) clinical signs and symptoms 
of acute respiratory distress: dyspnea, respiratory rate more 
than 24 breaths per minute, use of accessory muscles of res-
piration, presence of paradoxical breathing; and, (b) arterial 
blood gas (ABG) analysis with pH   7.35 and partial pres-
sure of oxygen in arterial blood (PaO2)/fraction of inspired 
oxygen concentration (FiO2) ratio less than 200 (or PaO2 less 
than 60 mm Hg). They were further classiﬁ  ed as type 1 or 
hypoxemic respiratory failure if partial pressure of carbon 
dioxide in arterial blood (PaCO2) was less than 45 mm Hg; 
and, type 2 or hypercapnic respiratory failure if PaCO2 was 
more than or equal to 45 mm Hg. Patients were excluded from 
the study if they met any of the following criteria: respiratory 
arrest, medically unstable condition (hypotension, uncon-
trolled cardiac ischemia/arrhythmia etc.), inability to protect 
airway (excess secretions, stuporous or comatose patient), 
abnormalities which preclude proper ﬁ  t of the interface 
(agitated or uncooperative patient, facial trauma or burns, 
facial surgery or facial anatomical abnormality).
Noninvasive ventilation was administered with the use of 
portable noninvasive ventilator VPAP II (ResMed, Sydney, 
Australia). NIPPV was delivered to patients in bed at an angle 
of 30–45° and in all patients a full face mask (UltraMirage, 
Sydney, Australia) was used as an interface for delivery of International Journal of COPD 2008:3(4) 739
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positive pressure. At the outset the patient was started on 
an IPAP of 8 and EPAP of 4 cm H2O. The pressures were 
gradually adjusted as tolerated based on continuous pulse 
oximetry (to achieve saturation of peripheral oxygen [SpO2] 
of 90%–92%), arterial blood gases (at one and four hours 
and periodically thereafter as clinically indicated), alleviation 
of patient’s dyspnea, decrease in respiratory rate and good 
patient – ventilator synchrony. Oxygen supplementation was 
provided through a port in the mask to keep SpO2   90%. 
Air leaks were frequently checked for, and the patient was 
constantly encouraged and reassured. The duration of NIPPV 
and the time to stop NIPPV was determined based on clinical 
judgment and arterial blood gas values.
At admission, the demographic details of patient were 
recorded which included age, sex, body mass index, etiology 
of ARF and the presence and absence of associated co-morbid 
illnesses. The disease severity was calculated using Acute 
Physiology and Chronic Health Evaluation (APACHE) II 
scores. We prospectively collected the data for heart rate, 
respiratory rate, arterial blood gases (pH, PaO2, PaCO2) at 
baseline, one and four hours.
The primary outcome was NIPPV failure, deﬁ  ned as 
the need for endotracheal intubation during the ICU stay 
due to inability to improve or stabilize gas exchange or 
dyspnea in one hour or failure to improve mental status 
within 60 minutes of initiating NIPPV in patients who were 
lethargic from CO2 retention or agitated from hypoxemia. 
Ultimately, clinical judgment was applied in the decision to 
intubate any patient. We also noted the time spent on NIV, 
the ICU and the hospital length of stay.
Statistical analysis was performed using the statistical 
package SPSS (version 10; SPSS Inc; Chicago, IL, USA). 
Results are presented in a descriptive fashion as number 
(percentage) or means (standard deviation) unless other-
wise stated. The differences between means of continuous 
and categorical variables were analyzed using Mann-
Whitney U and chi-square test respectively. Improvements 
in clinical (respiratory and heart rate) and arterial blood gas 
parameters (pH, PaO2, PaCO2) was analyzed using multiple 
analysis of variance (MANOVA) with Bonferroni adjust-
ment for multiple comparisons; the within-groups factor 
was time (zero, one and four hours), and the between-groups 
factor was the etiology of ARF (COPD vs other causes of 
ARF). Statistical signiﬁ  cance was assumed at a p-value of 
less than 0.05. Multivariate logistic regression analysis was 
performed to derive adjusted odds ratio (AOR) and 95% 
conﬁ  dence intervals (CI) using the following variables: 
gender, APACHE II scores, change in respiratory rate, pH, 
PaO2, PaCO2 in the ﬁ  rst hour after application of NIPPV 
and etiology (COPD vs other causes of ARF) to analyze 
the factors predicting failure of NIPPV (ie, requirement of 
endotracheal intubation).
Results
During the study period 248 patients were admitted in the 
RICU, and of these 63 (25.4%) patients met the inclusion 
criteria and were initiated on NIPPV. The most common 
etiology requiring initiation of NIPPV was acute exacerba-
tions of COPD (Table 1) with thirty-seven (58.7%) patients 
having evidence of hypercapnic acute respiratory failure. The 
baseline characteristics of patients included in the study are 
shown in Table 2. There were 40 male and 23 female patients 
with a mean (SD) age of 45.7 (16.6) years. Patients with ARF 
secondary to COPD were older, had higher APACHE II 
scores, lower respiratory rates, lower pH and higher PaCO2 
levels compared to other causes of ARF (Table 2).
The serial clinical and arterial blood gas parameters are 
shown in Table 3. After one hour there was a signiﬁ  cant 
improvement in clinical (decrease in respiratory rate and heart 
rate) and blood gas (decline in PaCO2 levels with increase 
in pH and PaO2 levels) parameters in patients successfully 
managed with NIPPV. At four hours, there was a decrement 
in respiratory rate, heart rate and increase in pH but no dif-
ference in PaO2 and PaCO2 levels. However, when the two 
groups (ARF – COPD vs others) were compared there was no 
difference in improvement of clinical and blood gas param-
eters between the two groups except the rate of decline of 
pH at one and four hours and PaCO2 at one hour which was 
signiﬁ  cantly faster in the COPD group (Table 3). The mean 
(SD) IPAP/EPAP administered was 17.6 (2.8)/8.4 (1.7) cm 
H2O and was administered for a mean duration of 19.6 hours. 
Table 1 Etiology of acute respiratory failure (n = 63)
Etiology Number (%)
Acute exacerbations of COPD 24 (38.1)
Others
 Pneumonia 15  (23.8)
  Sepsis-related lung injury 9 (14.3)
 Asthma 6  (9.5)
   Acute worsening of obstructive 
sleep apnea
6 (9.5)
  Post-extubation respiratory failure 3 (4.8)
Hypercapnic 37
Hypoxemic 26
Note: Numbers in parenthesis are percentages until otherwise stated.
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD 2008:3(4) 740
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The duration of ventilation (or the time to resolution of ARF) 
was not signiﬁ  cantly different in COPD when compared to 
other causes of ARF in patients successfully managed with 
NIPPV (Table 4).
Overall NIPPV was successful in 71.4% with three out 
of 24 (12.5%) patients in the COPD group and 15 out of 39 
(38.5%; pneumonia/ARDS, 12; asthma, one; post-extubation 
respiratory failure, two) patients in ARF due to other causes 
group requiring endotracheal intubation and invasive ventila-
tion respectively, and was statistically signiﬁ  cant (p = 0.03). 
The odds of NIPPV failure was 4.38 (95% conﬁ  dence inter-
vals [CI] 1.01–26.24) in ARF due to other causes compared 
to COPD–ARF. All the three patients requiring invasive 
ventilation in the COPD–ARF group died whereas seven 
patients in the ARF-other causes group died to multiple organ 
dysfunction. The ICU (mean [SD], 2.4 [1.1] in COPD–ARF 
and 3.4 [3] in ARF–other causes) and hospital stay (mean 
[SD], 3.5 [1.6] in COPD–ARF and 4 [3.1] in ARF–other 
causes) was found to be similar in the two groups.
Multivariate logistic regression analysis was performed 
to assess the factors predicting endotracheal intubation in 
patients ventilated with NIPPV (Table 4). In the univariate 
analysis, female gender, improvement in pH at one hour and 
the etiology of ARF were associated with favorable outcome 
(Table 5). However, in the multivariate model (Table 5), after 
adjustment (for gender, APACHE II scores and improvement 
in respiratory rate, pH, PaO2, PaCO2 at one hour) only the 
etiology which necessitated NIPPV ie, ARF secondary to 
COPD was associated with a successful outcome (odds ratio 
[OR] 0.23; 95% CI, 0.58–0.9).
Discussion
The results of this study show that NIPPV can be utilized 
as an effective modality in the management of ARF due to 
diverse etiologies. However, the success rate of NIPPV was 
signiﬁ  cantly higher for ARF due to COPD than other causes 
of ARF. In fact, in the multivariate analysis, the etiology of 
ARF necessitating NIV was the only signiﬁ  cant predictor 
Table 2 Baseline characteristics of patients with acute respiratory failure stratiﬁ  ed by etiology
Variable COPD (n = 24) Others (n = 39) Total (n = 63) P value
Age (years) 56 (11.8) 39.3 (16.1) 45.7 (16.6) 0.0001
Female gender, No. (%) 9 (37.5) 14 (35.9) 23 (36.5) 0.9
BMI (kg/m2) 21.7 (4.7) 25.4 (6.9) 24 (6.4) 0.02
Presence of other co-morbid 
illness, No. (%)
18 (75) 27 (69.2) 45 (71.4) 0.08
APACHE II scores 21.7 (4.8) 16.7 (4.8) 18.6 (5.4) 0.0001
Respiratory rate (breaths/min) 34.1 (7.4) 38.2 (7.8) 36.7 (7.9) 0.04
Heart rate (beats/min) 116.8 (16.9) 114.4 (19.3) 115.3 (18.3) 0.35
pH 7.27 (0.07) 7.36 (0.12) 7.33 (0.11) 0.002
PaO2/FiO2 198.9 (33) 149 (58.3) 168.2 (55.4) 0.001
PaCO2 (mm Hg) 73.1 (24.3) 43.3 (16.1) 54.6 (24.3) 0.0001
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FiO2, fraction of inspired oxygen concentration; PaCO2, partial pressure of carbon 
dioxide in arterial blood; PaO2, partial pressure of oxygen in the arterial blood.
Table 3 Serial clinical and arterial blood gas parameters during the ICU course of the two groups receiving NIPPV
ARF–COPD ARF–others
0 hour 1 hour 4 hour 0 hour 1 hour 4 hour
RR 34.1 (7.4) 31.7 (5.3)a 29.1 (3.5)b 38.2 (7.8) 33.7 (6.4)a 29.4 (4.3)b
HR 116.8 (16.9) 109.2 (11.7)a 101 (10.2)b 114.4 (19.3) 107.7 (17.7)a 97.3 (11.9)b
pH 7.27 (0.07) 7.337 (0.07)a 7.378 (0.07)b 7.36 (0.12) 7.376 (0.09)a,c 7.405 (0.06)b,d
PaO2 55.6 (16.1) 61.5 (9.7)a 64.2 (7.9) 52.9 (7.38) 64.1 (13.4)a 70.4 (10.8)
PaCO2 73.1 (24.3) 56.4 (16.5)a 53.6 (14.9) 43.3 (16.1) 40.4 (14.2)a,c 43.1 (13.5)
Notes: avalue at 1 hour signiﬁ  cantly different from that at baseline within the groups; bvalue at 4 hour signiﬁ  cantly different from that at 1 hour within the groups; cvalue at 
1 hour signiﬁ  cantly different from that at baseline between the two groups; dvalue at 4 hour signiﬁ  cantly different from that at 1 hour between the two groups.   A p-value less 
than 0.05 were taken as signiﬁ  cant. The differences between the means was analyzed using MANOVA with Bonferroni adjustment for multiple comparisons; the within-groups 
factor was time (0, 1 and 4 hours), and the between-groups factor was the etiology of ARF (COPD vs other causes of ARF).
Abbreviations: ARF, acute respiratory failure; COPD, chronic obstructive pulmonary disease; HR, heart rate; ICU, intensive care unit; NIPPV, noninvasive positive pressure 
ventilation; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in the arterial blood; RR, respiratory rate.International Journal of COPD 2008:3(4) 741
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of successful outcome. Even the severity of the illness at 
admission in the ICU as assessed by the APACHE II scores 
was not a signiﬁ  cant predictor of failure in our study. The 
success rate of NIPPV was 87.5% for ARF due to COPD 
and 61.5% for ARF due to other causes which are similar 
to reintubation rates described elsewhere both from India 
(Singh et al 2006; George et al 2007) and the European-
American countries (Antonelli et al 2001; Afessa et al 2002; 
Phua et al 2005). There is little doubt on the efﬁ  cacy of NIV 
in ARF due to COPD (Ram et al 2004) and cardiogenic 
pulmonary edema (Agarwal et al 2005). The role of NIV in 
other etiologies of ARF such as pneumonia, asthma, ARDS 
is controversial, and controlled trials for the use of NIV in 
acute exacerbations of obstructive sleep apnea, bronchiectasis 
and diffuse parenchymal lung diseases are lacking. This fact 
was also reﬂ  ected in this study with almost 40% failure rate 
with NIPPV in ARF due to other etiologies.
In general, the factors predicting success/failure with 
NIPPV in hypercapnic respiratory failure include pH at 
admission, pH after one hour of NIPPV trial and severity 
of underlying illness (Chevrolet et al 1991; Ambrosino et al 
1995; Meduri et al 1996; Wood et al 1998; Plant et al 2000, 
2001; Carlucci et al 2003; Girault et al 2003; Nava and 
Ceriana 2004; Carratù et al 2005). In patients with hypox-
emic respiratory failure the factors predicting the need for 
endotracheal intubation include age, severity of underlying 
illness, baseline PaO2/FiO2 scores and the presence or absence 
of pneumonia/ARDS (Antonelli et al 2001; Nava and Ceriana 
2004; Schettino et al 2008).
One important predictor of NIV failure has been 
the severity of the underlying illness as assessed by the 
APACHE II scores or similar scoring systems (Antonelli 
et al 2001; Phua et al 2005) although some studies have 
failed to demonstrate this observation (Benhamou et al 1992; 
Meduri et al 1996; Antón et al 2000; Lightowler and Elliott 
2000; Moretti et al 2000). Even in this study, the APACHE II 
scores did not predict NIPPV failure. The probable reason 
for this is the difference in the baseline characteristics of the 
study population in the two groups of ARF. Patients with 
ARF due to COPD were signiﬁ  cantly older when compared 
to other causes of ARF (mean age, 56 years in COPD group 
versus 39 years in the others; p   0.0001). This difference 
led to a higher APACHE II scores in the COPD population 
compared to the other group (mean APACHE II scores, 
21.7 in the COPD group versus 16.7 in the other group; 
p   0.0001).
There was a signiﬁ  cant improvement in clinical and 
blood gas values with the use of NIPPV in both the groups. 
However, the baseline clinical (heart rate, respiratory rate) 
and arterial blood gas parameters, and their serial values did 
Table 4 Outcome parameters during the ICU course of the two groups receiving NIPPV
Variable COPD (n = 24) Others (n = 39) Total (n = 63) P value
Duration of NIPPV** 15.8 (15.5) 21.9 (19.9) 19.6 (18.5) 0.2
Successful Outcome 21 (87.5) 24 (61.5) 45 (71.4) 0.03*
Duration of ICU stay 2.4 (1.1) 3.4 (3) 2.8 (2.1) 0.18
Duration of hospital stay 3.5 (1.6) 4 (3.1) 3.7 (2.3) 0.57
Mortality 3 (12.5) 7 (17.9) 10 (15.9) 0.66
Notes: *statistically signiﬁ  cant; **only in patients with successful outcomes.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; NIPPV, noninvasive positive pressure ventilation.
Table 5 Factors predicting outcome of NIPPV: univariate and multivariate analysis
Variable Success (n = 45) Failure (n = 18) Crude OR (95% CI) Adjusted OR (95% CI)
Female gender, No 20 3 0.25 (0.06–0.25)* 0.24 (0.05–1.11)
APACHE II scores 19.1 (5.6) 17.5 (4.8) 0.95 (0.86–1.05) 1.06 (0.91–1.24)
Delta RR(0–1 hr) −4.3 (6.7) −2.1 (8.3) 1.05 (0.96–1.14) 1.03 (0.94–1.14)
Delta pH(0–1 hr) 0.04 (0.06) 0.005 (0.06) 0 (0–0.32)* 0 (0–18.3)
Delta PaO2 (0–1 hr) 10.7 (9.5) 6.4 (9.2) 0.99 (0.95–1.02) 0.96 (0.9–1.01)
Delta PaCO2 (0–1 hr) 5 (19.8) 13.4 (18.6) 1.02 (0.99–1.05) 1 (0.96–1.04)
Etiology (COPD: Others) 21:24 3:15 0.23 (0.58–0.9)* 0.12 (0.02–0.95)*
Note: *P   0.05.
Abbreviations: (0–1), baseline minus one hour;   APACHE, acute physiology and chronic health evaluation; CI, conﬁ  dence interval; COPD, chronic obstructive pulmonary 
disease; OR, odds ratio; PaCO2, partial pressure of carbon dioxide in arterial blood; PaO2, partial pressure of oxygen in the arterial blood; RR, respiratory rate.International Journal of COPD 2008:3(4) 742
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not predict successful outcome in this study. The reason for 
this is the fact that majority of the failures have occurred in 
the ARF due to other causes group wherein the failure rate of 
NIPPV was very high. In this group (majority were patients 
with pneumonia/ARDS), a transient improvement in the 
clinical and blood gas parameter does occur with NIPPV but 
the underlying process such as sepsis or pneumonia is not 
affected by NIPPV; and improvement with antibiotics and 
other supportive measures takes at least 24–48 hours which 
can cause late NIPPV failure despite an improvement in the 
early hours (Moretti et al 2000; Antonelli et al 2001; Carlucci 
et al 2001; Schettino et al 2008). This point is further reﬂ  ected 
in a recent study in which the failure rate of NIPPV for acute 
hypoxemic respiratory failure was as high as 60% (Schettino 
et al 2008). Even in our study, the failure rate of NIPPV was 
50% in the pneumonia/ARDS group of patients. Also there 
are a subset of patients who initially seem to respond to 
NIPPV but then fail to improve with NIV and this cohort of 
patients are termed as “late NIV failures” (Moretti et al 2000; 
Carratù et al 2005). In patients with late NIPPV failures, the 
improvement in clinical parameters and arterial blood gases 
does not predict successful outcome with NIPPV.
There is also a great importance of international 
comparison of ICU data. However, there is a paucity of data 
from India on the use of NIPPV in ARF. In fact, only two 
prospective studies have been published which have investi-
gated the use of NIPPV in patients with ARF of varied causes 
(Singh et al 2006; George et al 2007). However, both the 
studies have certain limitations. One study had disproportion-
ate number of patients with hypercapnic respiratory failure 
(36 hypercapnic ARF and 4 hypoxemic ARF) (George et al 
2007). Although both the studies suggested certain factors 
that predict the success or failure of NIPPV, neither of the two 
studies had used multivariate analysis for predicting the 
outcome of NIPPV which decreases the robustness and 
applicability of their results. Although there are numerous 
studies determining the factors predicting failure of NIPPV 
in acute respiratory failure due to COPD and other causes, 
there is none from the Indian subcontinent and this study 
provides the Indian perspective on this issue.
The strength of this study is the prospective nature of 
the study and the fact that robust statistical methods have 
been used for analysis of the data so that the results can be 
interpreted with conﬁ  dence. We have used MANOVA for 
repeated measures which can test more complex hypotheses 
and is thus more powerful than using multiple t-tests. 
Similarly we have used multivariate analysis for assessing the 
risk factors affecting NIPPV failure; this statistical method 
assumes signiﬁ  cance only after correcting for other covariates 
removing the effect of confounding.
Finally, our study is also not without limitations. The 
major limitations of our study include the relatively small 
number of patients (although it is the largest number of 
patient data published from India on NIV). Thus many of the 
conclusions regarding risk factors in our study have limita-
tions because of the small numbers of patients in each group; 
the small data set does not allow for a valid assessment, of 
whether some of these conditions in the study population may 
or may not be a contributing factor for success or failure of 
NIPPV. Currently, patients who require NIPPV are managed 
with critical care ventilators which have facilities for better 
oxygen delivery (due to the presence of oxygen blender) and 
better patient monitoring facilities (Liesching et al 2003). 
However, when this study was performed, due to resource 
constraints, the RICU possessed only a domiciliary nonin-
vasive ventilator and was thus used in this study.
As the demand for NIV increases, its use should be limited 
to settings in which there is the strongest evidence of beneﬁ  t 
from high quality clinical trials such as in acute exacerbations 
of COPD, cardiogenic pulmonary edema and in patients at 
high risk of post-extubation respiratory failure (Ram et al 
2004; Agarwal et al 2005, 2007). And, conversely, the use 
of NIV in septic patients and others with ill-deﬁ  ned acute 
respiratory failure should be curtailed (Antonelli et al 2001; 
Agarwal et al 2006). The results of our study are similar to 
many other studies which suggest that NIPPV is likely to 
have limited applicability in ARF due to causes other than 
COPD and acute cardiogenic pulmonary edema (Demoule 
et al 2006; Schettino et al 2008).
In conclusion, this study demonstrates that NIPPV is 
an effective modality in preventing endotracheal intubation 
in ARF due to COPD but has limited applicability in ARF 
secondary to other causes. Within limitations of the current 
study, the study suggests that it is the etiology of ARF which 
is the most important predictor of NIPPV failure.
Disclosure
The authors declare no conﬂ  icts of interest in this work.
References
Afessa B, Morales IJ, Scanlon PD, et al. 2002. Prognostic factors, clinical 
course, and hospital outcome of patients with chronic obstructive pul-
monary disease admitted to an intensive care unit for acute respiratory 
failure. Crit Care Med, 30:1610–5.
Agarwal R, Aggarwal AN, Gupta D, et al. 2005. Non–invasive ventilation in 
acute cardiogenic pulmonary oedema. Postgrad Med J, 81:637–43.
Agarwal R, Aggarwal AN, Gupta D, et al. 2007. Role of noninvasive 
positive-pressure ventilation in postextubation respiratory failure: a 
meta-analysis. Respir Care, 52:1472–9.International Journal of COPD 2008:3(4) 743
NIPPV in COPD vs other causes of ARF
Agarwal R, Reddy C, Aggarwal AN, et al. 2006. Is there a role for 
noninvasive ventilation in acute respiratory distress syndrome? A meta-
analysis. Respir Med, 100:2235–8.
Ambrosino N, Foglio K, Rubini F, et al. 1995. Non-invasive mechanical 
ventilation in acute respiratory failure due to chronic obstructive 
pulmonary disease: correlates for success. Thorax, 50:755–7.
Antón A, Güell R, Gómez J, et al. 2000. Predicting the result of noninvasive 
ventilation in severe acute exacerbations of patients with chronic airﬂ  ow 
limitation. Chest, 117:828–33.
Antonelli M, Conti G, Moro ML, et al. 2001. Predictors of failure of 
noninvasive positive pressure ventilation in patients with acute 
hypoxemic respiratory failure: a multi-center study. Intensive Care 
Med, 27:1718–28.
Azoulay E, Alberti C, Bornstain C, et al. 2001. Improved survival in cancer 
patients requiring mechanical ventilatory support: impact of noninvasive 
mechanical ventilatory support. Crit Care Med, 29:519–25.
Benhamou D, Girault C, Faure C, et al. 1992. Nasal mask ventilation in acute 
respiratory failure. Experience in elderly patients. Chest, 102:912–7.
Brochard L. 2003. Mechanical ventilation: invasive versus noninvasive. 
Eur Respir J, 23(Suppl 47):S31–7.
Brochard L, Mancebo J and Elliott MW. 2002. Noninvasive ventilation for 
acute respiratory failure. Eur Respir J, 19:712–21.
Budweiser S, Jorres RA, Riedl T, et al. 2007. Predictors of survival in 
COPD patients with chronic hypercapnic respiratory failure receiving 
noninvasive home ventilation. Chest, 131:1650–8.
Carlucci A, Delmastro M, Rubini F, et al. 2003. Changes in the practice 
of non-invasive ventilation in treating COPD patients over 8 years. 
Intensive Care Med, 29:419–25.
Carlucci A, Richard JC, Wysocki M, et al. 2001. Noninvasive versus 
conventional mechanical ventilation. An epidemiologic survey. Am J 
Respir Crit Care Med, 163:874–80.
Carratù P, Bonﬁ  tto P, Dragonieri S, et al. 2005. Early and late failure of 
noninvasive ventilation in chronic obstructive pulmonary disease with 
acute exacerbation. Eur J Clin Invest, 35:404–9.
Cheung MT, Yam LY, Lau CW, et al. 2000. Use of non-invasive positive-
pressure ventilation for acute respiratory failure: prospective study. 
Hong Kong Med J, 6:361–7.
Chevrolet JC, Jolliet P, Abajo B, et al. 1991. Nasal positive pressure ven-
tilation in patients with acute respiratory failure. Difﬁ  cult and time-
consuming procedure for nurses. Chest, 100:775–82.
Confalonieri M, Garuti G, Cattaruzza MS, et al. 2005. A chart of failure 
risk for noninvasive ventilation in patients with COPD exacerbation. 
Eur Respir J, 25:348–55.
Demoule A, Girou E, Richard JC, et al. 2006. Increased use of noninva-
sive ventilation in French intensive care units. Intensive Care Med, 
32:1747–55.
George IA, John G, John P, et al. 2007. An evaluation of the role of nonin-
vasive positive pressure ventilation in the management of acute respi-
ratory failure in a developing country. Indian J Med Sci, 61:495–504.
Girault C, Briel A, Hellot MF, et al. 2003. Noninvasive mechanical ventila-
tion in clinical practice: a 2-year experience in a medical intensive care 
unit. Crit Care Med, 31:552–9.
Hess DR. 2004. The evidence for noninvasive positive-pressure ventilation 
in the care of patients in acute respiratory failure: a systematic review 
of the literature. Respir Care, 49:810–29.
Jaber S, Delay JM, Chanques G, et al. 2005. Outcomes of patients with acute 
respiratory failure after abdominal surgery treated with noninvasive 
positive pressure ventilation. Chest, 128:2688–95.
Keenan SP, Sinuff T, Cook DJ, et al. 2004. Does noninvasive positive 
pressure ventilation improve outcome in acute hypoxemic respiratory 
failure? A systematic review. Crit Care Med, 32:2516–23.
Lellouche F. 2007. Noninvasive ventilation in patients with hypoxemic 
acute respiratory failure. Curr Opin Crit Care, 13:12–9.
Liesching T, Kwok H, Hill NS. 2003. Acute applications of noninvasive 
positive pressure ventilation. Chest, 124:699–713.
Lightowler JV, Elliott MW. 2000. Predicting the outcome from NIV for 
acute exacerbations of COPD. Thorax, 55:815–6.
Meduri GU, Turner RE, Abou-Shala N, et al. 1996. Noninvasive positive pres-
sure ventilation via face mask. First-line intervention in patients with acute 
hypercapnic and hypoxemic respiratory failure. Chest, 109:179–93.
Moretti M, Cilione C, Tampieri A, et al. 2000. Incidence and causes of 
non-invasive mechanical ventilation failure after initial success. 
Thorax, 55:819–25.
Nava S, Ceriana P. 2004. Causes of failure of noninvasive mechanical 
ventilation. Respir Care, 49:295–303.
Phua J, Kong K, Lee KH, et al. 2005. Noninvasive ventilation in hyper-
capnic acute respiratory failure due to chronic obstructive pulmonary 
disease vs. other conditions: effectiveness and predictors of failure. 
Intensive Care Med, 31:533–9.
Plant PK, Owen JL, Elliott MW. 2000. Early use of non-invasive ventilation 
for acute exacerbations of chronic obstructive pulmonary disease on 
general respiratory wards: a multicentre randomised controlled trial. 
Lancet, 355:1931–5.
Plant PK, Owen JL, Elliott MW. 2001. Non-invasive ventilation in acute 
exacerbations of chronic obstructive pulmonary disease: long term 
survival and predictors of in-hospital outcome. Thorax, 56:708–12.
Ram FSF, Picot J, Lightowler J, et al. 2004. Non-invasive positive pressure 
ventilation for treatment of respiratory failure due to exacerbations 
of chronic obstructive pulmonary disease. Cochrane Database Syst 
Rev, 3:CD004104.
Schettino G, Altobelli N, Kacmarek RM. 2008. Noninvasive positive-
pressure ventilation in acute respiratory failure outside clinical trials: 
experience at the Massachusetts General Hospital. Crit Care Med, 
36:441–7.
Singh VK, Khanna P, Rao BK, et al. 2006. Outcome predictors for 
non-invasive positive pressure ventilation in acute respiratory failure. 
J Assoc Physicians India, 54:361–5.
Soo Hoo GW, Santiago S, Williams AJ. 1994. Nasal mechanical 
ventilation for hypercapnic respiratory failure in chronic obstructive 
pulmonary disease: determinants of success and failure. Crit Care 
Med, 22:1253–61.
Wood KA, Lewis L, Von Harz B, et al. 1998. The use of noninvasive 
positive pressure ventilation in the emergency department: results of a 
randomized clinical trial. Chest, 113:1339–46.